title: Oral idarubicin, dexamethasone and vincristine (VID) in the treatment of multiple myeloma.
abstract: In order to replace the central venous line necessary for continuous infusion of vincristine and doxorubicin with high-dose dexamethasone (VAD) and to avoid hospitalization, we evaluated the efficacy and toxicity of oral idarubicin, vincristine and dexamethasone (VID) in patients with multiple myeloma. Vincristine (1.6 mg/m2, max 2 mg) was given as a bolus injection on day 1. Idarubicin was given in capsules 10 mg/m2/day for days 1-4 with an intraindividual dose escalation, 40 mg dexamethasone were given on days 1-4, 9-12, 17-20. Treatment cycles were repeated every 28 days. At this interim analysis, 53 patients have been entered into the ongoing trial; 46 patients are evaluable for toxicity. The median age was 60 years (interquartile range, 52-65). 46% were primary or secondary refractory, 20% had previously been treated with VAD and 30% had previously untreated disease, 4% had two or more relapses. Four patients died within 2 months from entry and were considered as early deaths (8.7%). 45% of the 42 patients evaluable for efficacy achieved a partial remission and 26% a minor remission. The median reduction of the M-component was 43% (interquartile range, 25-64%). VID is an effective and convenient alternative to VAD even in relapsed or refractory patients.
authors.affiliation: Medizinische Universitätsklinik und Poliklinik, Allgemeine Innere Medizin, University of Bonn, Germany.
authors.forename: A
authors.initials: A
authors.lastname: Glasmacher
authors.forename: T
authors.initials: T
authors.lastname: Haferlach
authors.forename: M
authors.initials: M
authors.lastname: Gorschlüter
authors.forename: J
authors.initials: J
authors.lastname: Mezger
authors.forename: C
authors.initials: C
authors.lastname: Maintz
authors.forename: M R
authors.initials: MR
authors.lastname: Clemens
authors.forename: Y
authors.initials: Y
authors.lastname: Ko
authors.forename: C
authors.initials: C
authors.lastname: Hahn
authors.forename: R
authors.initials: R
authors.lastname: Ubelacker
authors.forename: R
authors.initials: R
authors.lastname: Kleinschmidt
authors.forename: F
authors.initials: F
authors.lastname: Gieseler
mesh_terms: D000284:Administration, Oral; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003907:Dexamethasone / Q000008:administration & dosage / Q000009:adverse effects; D004334:Drug Administration Schedule; D005260:Female; D006801:Humans; D015255:Idarubicin / Q000008:administration & dosage* / Q000009:adverse effects; D007070:Immunoglobulin A / Q000097:blood; D007074:Immunoglobulin G / Q000097:blood; D007132:Immunoglobulin Isotypes / Q000097:blood; D007147:Immunoglobulin Light Chains / Q000097:blood; D008297:Male; D008875:Middle Aged; D009101:Multiple Myeloma / Q000188:drug therapy* / Q000276:immunology / Q000401:mortality / Q000473:pathology; D009367:Neoplasm Staging; D015996:Survival Rate; D014750:Vincristine / Q000008:administration & dosage / Q000009:adverse effects
chemical_list: D007070:Immunoglobulin A; D007074:Immunoglobulin G; D007132:Immunoglobulin Isotypes; D007147:Immunoglobulin Light Chains; D014750:Vincristine; D003907:Dexamethasone; D015255:Idarubicin